949-P: Android Artificial Pancreas System Use among Patients with Type 1 Diabetes Mellitus in China-A Real-World Study

Objective: The real-world study aimed to investigate the current status of Android artificial pancreas system (APS) use among patients with type 1 diabetes mellitus (T1DM) in China, where market-approved commercial APS is unavailable. Methods: The healthcare providers of China's largest online T1DM community (TTQ) helped build up AndroidAPS using a compatible insulin pump, real-time continuous glucose monitoring (CGM), and a heuristic-based algorithm. Patients with T1DM who used AndroidAPS for at least 3 months between January 2020 and July 2023 were included. The baseline data and main glycemic metrics during the last 3 months after using AndroidAPS were collected. Results: We included 191 patients (56 non-adults and 135 adults) with a median age of 24.80 (15.83, 32.74) yrs, T1DM duration of 6.01(1.63,8.58) yrs, and body mass index (BMI) of 20.74(18.51,22.34) kg/m2. The duration of APS use was 153(114.00,206.00) days. After using AndroidAPS, HbA1c was decreased from 7.1(6.4,8.5) % to 6.3(5.6,6.8) % (p180mg/dL), time below range (TBR,